Status:
COMPLETED
An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis
Lead Sponsor:
Pfizer
Conditions:
Interstitial Cystitis
Painful Bladder Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether PD 0299685 is effective in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain, urinary urgency and...
Eligibility Criteria
Inclusion
- Men and women over 18 years of age with moderate to severe interstitial cystitis defined by pain score.
- Women must not be pregnant or lactating, They may be post-menopausal, surgically sterilized or using an appropriate method of contraception.
Exclusion
- History of interstitial cystitis less than 6 months
- History of current or recurrent urinary tract infections, or genitourinary cancer
- Any previous urinary diversion procedure with or without bladder removal, bladder augmentation
- Use of certain drugs given into the bladder up to 1 month prior to study entry
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT00739739
Start Date
August 1 2008
End Date
January 1 2010
Last Update
March 28 2011
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
2
Pfizer Investigational Site
Goodyear, Arizona, United States, 85395
3
Pfizer Investigational Site
Litchfield Park, Arizona, United States, 85340
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85032